Eli Lilly bags an early-stage biotech for the neuro team — paying $135M cash and offering $1B-plus in milestones
Eli Lilly is snapping up a little Cambridge-based biotech to add to their neuro group.
The pharma giant is getting Disarm Therapeutics and its SARM1 inhibitors for axonal degeneration, which has potential to be used for peripheral neuropathy, ALS and MS.
It’s costing Lilly $135 million cash plus up to $1.225 billion in milestones — if it all pays out. In return, they’re getting a biotech that posted preclinical results last fall, with a long haul ahead in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
